Shares in Ardelyx Inc.
ARDX,
+2.67%
plummeted more than 70% in after-hours trading Monday, following the biopharmaceutical company’s announcement that the Food and Drug Administration appears unlikely to approve a drug for dialysis patients. Ardelyx…

Click here to view the original article.